SwitzerlandSwitzerland

Santhera publishes pivotal trial results of idebenone and goes for EU approval

26.07.2011

Liestal/Newscastle – Swiss Santhera Pharmaceuticals and researchers from Newcastle University have published results from a pivotal clinical trial demonstrating that the firm’s synthetic coenzyme Q10 derivative idebenone significantly improves vision and perception of colour in a subgroup of patients with the rare mitochondrial disease Leber's Hereditary Optic Neuropathy (LHON). The 10,000 to 20,000 patients in Europe and the US, which suffer from the maternally inherited condition, initially lose the sight in one eye due to a malfunction of complex I of the mitochondrial respiratory chain and subsequent retinal apoptosis. Typically, they lose the sight in their other eye within the next 3 to 6 months (so called discordant visual acuity). Researchers from Newcastle, Munich, and Montreal now demonstrated for the first time in 85 patients, that treatment with a 900mg dose of idebenone over two years could significantly improve visual acuity in a patient subgroup carrying the G11778A or G3460A mitochondrial DNA mutations, which are found in 80% of all LHON patients.
The Newscastle group led by Professor Patrick Chinnery reported that idebenone treatment resulted in a marked improvement of vision in severely affected patients, who were not able to read any letter on a chart. In nine blind patients (12 eyes) out of 36 patients (61 eyes) taking idebenone, vision improved to an extent that patients were able to read at least one row of letters on the chart (20%). In contrast not a single patient of the 26 who were taking the placebo improved to that extent.
The results published in yesterday’s issue of BRAIN are part of a data package accepted by the EU drug authority on July 22th which now reviews the firm’s MAA in this indication. Market approval in LHON could be expected at the end of 2012 earliest, according to the Swiss specialist for neuromuscular diseases. The drug will be available trough a Named Patient Programme until the EMA has come to a decision. The greatest improvement was seen in patients who had deteriorated in one eye more than the other. The RHODOS study does not deliver data from patients who have been affected from the disease for more than 5 years. Idebenone has already gotten market approval in Canada as treatment for Friedreichs ataxia but was rejected the the EMA in this indication.

SwitzerlandSwitzerland

22.08.2011

Liestal – Swiss Santhera Pharmaceuticals and researchers from Newcastle University have published the results from a pivotal clinical trial demonstrating that the firm’s synthetic coenzyme Q10 derivative idebenone significantly...

SwitzerlandSwitzerland

18.08.2011

Basel – Swiss pharma and diagnostics major Roche AG has agreed to buy privately-held Heidelberg-based mtm laboratories AG, a specialist for kits detecting pre-stages of cervical cancer, for up to EUR190m. Under the terms of the...

SwitzerlandSwitzerland

16.08.2011

Reinach – Evolva SA has got its hands on up to €30m of fresh capital. The Swiss specialist for synthetic biology announced that it has entered into a Standby Equity Distribution Agreement (SEDA) with YA Global Master SPV Ltd. (YA...

SwitzerlandSwitzerland

15.08.2011

Basel/Waltham - Expecting to be bought by Novartis, U.S. biopharmaceutical firm Proteon Therapeutics Inc. has delivered a new $15.2 million financing. The Swiss pharmaceutical company Novartis obtained exclusive option to acquire...

SwitzerlandSwitzerland

03.08.2011

Zurich - Most of the European men share the DNA of the well known Egyptian pharaoh, Tutankhamun, also called the boy King Tut. According to geneticists at Zurich-based genealogy firm iGENEA, up to 70 percent of British men and...

SwitzerlandSwitzerland

13.07.2011

A big financier of biotech deals could be back on track soon. Novartis is interested in further acquisitions, CEO Joe Jimenez said in an interview published by the "Aargauer Zeitung", a Switzerland- based newspaper.The drugmaker...

SwitzerlandSwitzerland

11.06.2011

Basel – Swiss crop group Syngenta plans to construct a new biotech research facility adjacent to its existing research campus at the Research Triangle Park in North Carolina (US). The US$71m investment is scheduled to begin in...

SwitzerlandSwitzerland

10.06.2011

Zurich – Overexpression of two microRNAs trigger development of insulin resistance, a hallmark of type II diabetes which affects about 20% of the elderly (aged 55-74) in the western world. In Nature, a research team headed by...

Displaying results 31 to 40 out of 276

< Previous 31-40 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-switzerland/browse/3/article/santhera-publishes-pivotal-trial-results-of-idebenone-and-goes-for-eu-approval.html

Events

All Events

Stock list

All quotes

TOP

  • NOVACYT (F)4.98 EUR5.96%
  • STALLERGENES (F)53.50 EUR4.37%
  • SUMMIT (UK)4.03 GBP3.87%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • THROMBOGENICS (B)9.54 EUR-5.07%

TOP

  • WILEX (D)3.15 EUR314.5%
  • SANTHERA (CH)68.55 CHF90.4%
  • ADDEX (CH)4.08 CHF82.1%

FLOP

  • MERCK KGAA (D)65.43 EUR-48.6%
  • HYBRIGENICS (F)1.77 EUR-29.2%
  • PROSENSA (NL)9.81 USD-22.6%

TOP

  • SANTHERA (CH)68.55 CHF3489.0%
  • GW PHARMACEUTICALS (UK)427.00 GBP729.1%
  • PAION (D)2.79 EUR316.4%

FLOP

  • CYTOS (CH)0.26 CHF-92.4%
  • EVOCUTIS (UK)0.21 GBP-91.8%
  • THROMBOGENICS (B)9.54 EUR-69.5%

No liability assumed, Date: 25.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...


Current issue

All issues

Product of the week

Products